SAB Biotherapeutics - SABS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $15.50
  • Forecasted Upside: 231.55%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.68
▲ +0.17 (3.77%)

This chart shows the closing price for SABS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SAB Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SABS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SABS

Analyst Price Target is $15.50
▲ +231.55% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for SAB Biotherapeutics in the last 3 months. The average price target is $15.50, with a high forecast of $25.00 and a low forecast of $6.00. The average price target represents a 231.55% upside from the last price of $4.68.

This chart shows the closing price for SABS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 investment analysts is to moderate buy stock in SAB Biotherapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/2/2024Chardan CapitalBoost TargetBuy ➝ Buy$3.00 ➝ $25.00Low
4/2/2024HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $6.00Low
1/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$1.00 ➝ $10.00Low
11/14/2023HC WainwrightLower TargetBuy ➝ Buy$2.00 ➝ $1.00Low
10/5/2023LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
8/21/2023HC WainwrightLower TargetBuy ➝ Buy$4.00 ➝ $2.00Low
4/13/2023HC WainwrightReiterated RatingBuy$4.00Low
4/3/2023HC WainwrightReiterated RatingBuy$4.00Low
11/29/2022HC WainwrightInitiated CoverageBuy$4.00Low
8/11/2022Chardan CapitalLower TargetBuy$7.00 ➝ $3.00Low
8/11/2022Robert W. BairdLower Target$8.00 ➝ $4.00Low
5/13/2022Chardan CapitalLower Target$10.00 ➝ $7.00High
4/1/2022Chardan CapitalLower TargetBuy$17.00 ➝ $10.00Low
12/2/2021Northland SecuritiesBoost TargetOutperform$18.00 ➝ $21.00High
11/25/2021Robert W. BairdReiterated RatingBuy$23.00High
11/5/2021Chardan CapitalInitiated CoverageBuy$17.00Low
11/1/2021Robert W. BairdInitiated CoverageOutperform$23.00High
(Data available from 4/14/2019 forward)

News Sentiment Rating

-0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/17/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/17/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/16/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/16/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
SAB Biotherapeutics logo
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
Read More

Today's Range

Now: $4.68
Low: $4.54
High: $4.68

50 Day Range

MA: $5.00
Low: $4.17
High: $6.00

52 Week Range

Now: $4.68
Low: $4.00
High: $14.50

Volume

3,497 shs

Average Volume

11,938 shs

Market Capitalization

$43.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of SAB Biotherapeutics?

The following equities research analysts have issued research reports on SAB Biotherapeutics in the last twelve months: Chardan Capital, HC Wainwright, and LADENBURG THALM/SH SH.
View the latest analyst ratings for SABS.

What is the current price target for SAB Biotherapeutics?

2 Wall Street analysts have set twelve-month price targets for SAB Biotherapeutics in the last year. Their average twelve-month price target is $15.50, suggesting a possible upside of 231.6%. Chardan Capital has the highest price target set, predicting SABS will reach $25.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for SAB Biotherapeutics in the next year.
View the latest price targets for SABS.

What is the current consensus analyst rating for SAB Biotherapeutics?

SAB Biotherapeutics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SABS.

What other companies compete with SAB Biotherapeutics?

How do I contact SAB Biotherapeutics' investor relations team?

SAB Biotherapeutics' physical mailing address is 300 W. 41ST STREET SUITE 202, MIAMI BEACH FL, 33140. The company's listed phone number is 605-679-6980 and its investor relations email address is [email protected]. The official website for SAB Biotherapeutics is www.bigcypressaccorp.com. Learn More about contacing SAB Biotherapeutics investor relations.